Overview

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Status:
Not yet recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the efficacy and safety of the combination of Toripalimab and Surufatinib for Locally Advanced Thyroid Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University